<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00453934</url>
  </required_header>
  <id_info>
    <org_study_id>V4001</org_study_id>
    <nct_id>NCT00453934</nct_id>
  </id_info>
  <brief_title>Patient Preference of h-Patch vs. Pen or Needle/Syringe as Insulin Administration Device</brief_title>
  <official_title>h-Patch vs. Pen or Needle and Syringe as Insulin Administration Device in Type 1 or 2 Diabetes Patients Using MDI: Patient Preference and Glycemic Control After Switch in an Open-Label, Randomized Cross-Over Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Valeritas, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Valeritas, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to compare patient preference of the h-Patch as&#xD;
      delivery device for insulin lispro compared with either an insulin pen or needle and syringe&#xD;
      in patients with diabetes, either Type 1 or Type 2, on stable multiple daily injection&#xD;
      regimens. This will be assessed using an accepted preference scale.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with Type 1 Diabetes have an absolute deficiency in insulin production and benefit&#xD;
      from physiologic insulin replacement, defined as administration of background and mealtime&#xD;
      insulin. More than half of patients with Type 2 diabetes (T2DM) have less than 50% of their&#xD;
      beta cell function at the time of diagnosis. Because of this, these patients would also&#xD;
      benefit from the physiologic delivery of insulin. Currently, 4 or more injections per day are&#xD;
      required to deliver the various different available insulins in a physiologic manner.&#xD;
      Valeritas has developed the h-Patch, a device suitable to make the delivery of basal and&#xD;
      bolus insulin effective, simple and discrete. This study will measure patient preference,&#xD;
      glucose control and safety of the h-Patch compared with patients' previous therapy. Patients&#xD;
      previous therapy will be multiple daily injections delivered either by pens or needle and&#xD;
      syringe.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Endpoint no longer deemed meaningful&#xD;
  </why_stopped>
  <start_date>May 2007</start_date>
  <completion_date type="Actual">September 2007</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <secondary_outcome>
    <measure>Mean glucose using CGM.</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose SD, MAGE, Proportion of 24 hours in euglycemic range 70-160 mg/dl, using CGM.</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>End of Study Patient Questions</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hypoglycemia</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of time with glucose &lt; 70 mg/dl, from CGM.</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number and type of adverse events.</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">11</enrollment>
  <condition>Type 1 Diabetes</condition>
  <condition>Type 2 Diabetes</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>h-Patch</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Diagnosis of Type 1or Type 2 diabetes mellitus for at least a year&#xD;
&#xD;
          2. Stable insulin regimen for at least 3 months consisting of multiple daily injections&#xD;
             of human regular or rapid acting insulin at meal times and long or intermediate acting&#xD;
             insulin as basal. In this protocol multiple daily injections requires at least three&#xD;
             injections daily.&#xD;
&#xD;
          3. Total daily insulin dose between 50 and 80 units.&#xD;
&#xD;
          4. If patient is Type 2, can be treated with metformin and/or a thiazolidinedione and/or&#xD;
             a sulfonylurea, but other diabetes drugs including α-glucosidase inhibitors,&#xD;
             meglitinides, pramlintide exenatide, and DPP-IV's are excluded.&#xD;
&#xD;
          5. HbA1c &gt; 7.0% and &lt; 9.0%.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Recurrent major hypoglycemia or prolonged unstable blood glucose control (as judged by&#xD;
             the Investigator).&#xD;
&#xD;
          2. Use of other diabetes drugs including α-glucosidase inhibitors, meglitinides,&#xD;
             pramlintide, exenatide or DPP-IV inhibitors (metformin and/or a thiazolidinedione&#xD;
             and/or a sulfonylurea are allowed).&#xD;
&#xD;
          3. Intend to use any other concomitant drug therapy (prescription or over-the-counter&#xD;
             medications) that can affect blood glucose levels.&#xD;
&#xD;
          4. Have used systemic glucocorticoids within 1 month prior to Screening or currently on&#xD;
             glucocorticoids.&#xD;
&#xD;
          5. Have a history of drug or alcohol abuse within 1 year prior to Screening Visit.&#xD;
&#xD;
          6. Have a history or presence of cardiovascular, respiratory, hepatic, renal,&#xD;
             gastrointestinal, or neurological disease that would, in the investigator's opinion,&#xD;
             preclude safe participation in the study.&#xD;
&#xD;
          7. Have a history of major surgery, e.g. laparotomy, thoracotomy, open orthopedic&#xD;
             procedure, etc. within 3 months prior to Screening Visit.&#xD;
&#xD;
          8. Evidence of significant neuropsychiatric disease.&#xD;
&#xD;
          9. Have participated in a medical, surgical, or pharmaceutical investigational new&#xD;
             drug/device study in the last 30 days or ≤ 5 half-lives of the investigational drug,&#xD;
             whichever is longer, prior to Screening Visit.&#xD;
&#xD;
         10. Blood donation of 500 ml or more in the last 2 months prior to Screening Visit.&#xD;
&#xD;
         11. Evidence of significant active hematological disease.&#xD;
&#xD;
         12. Acute infection with fever.&#xD;
&#xD;
         13. Hemoglobin &lt; 10 g/dL; AST, ALT ≥ 1.5 times the upper reference limit at Screening.&#xD;
&#xD;
         14. Uncontrolled treated/untreated hypertension (systolic blood pressure &gt; 155 mmHg and&#xD;
             diastolic blood pressure &gt; 90 mmHg).&#xD;
&#xD;
         15. History of proliferative retinopathy or maculopathy requiring acute treatment&#xD;
&#xD;
         16. Mental incapacity, unwillingness or language barrier precluding adequate understanding&#xD;
             or co-operation.&#xD;
&#xD;
         17. Any condition that the Investigator and/or Sponsor feel would interfere with trial&#xD;
             participation or evaluation of results&#xD;
&#xD;
         18. Pregnancy, breast-feeding, intention of becoming pregnant for female patients of&#xD;
             child-bearing potential.&#xD;
&#xD;
             -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark S Kipnes, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Diabetes and Glandular Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Diabetes and Glandular Research</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2007</verification_date>
  <study_first_submitted>March 27, 2007</study_first_submitted>
  <study_first_submitted_qc>March 28, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 29, 2007</study_first_posted>
  <last_update_submitted>December 5, 2007</last_update_submitted>
  <last_update_submitted_qc>December 5, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 6, 2007</last_update_posted>
  <keyword>Diabetes</keyword>
  <keyword>Type 1 Diabetes</keyword>
  <keyword>Type 2 Diabetes</keyword>
  <keyword>Physiologic Insulin</keyword>
  <keyword>Basal Insulin</keyword>
  <keyword>Bolus Insulin</keyword>
  <keyword>Mealtime insulin</keyword>
  <keyword>Insulin patch</keyword>
  <keyword>Multiple daily injections</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

